Results 1 to 10 of about 7,933 (100)

Hydrophobically modified polyelectrolytes as potential drugs reservoirs of n-alkyl-nitroimidazoles [PDF]

, 2007
Indexación: ScieloThe solubilization of three commercial drugs (ornindazole, metronidazole and tinidazole) and model compounds (N-alkyl-2-methyl-4-nitroimidazoles) on aggregates formed by anionic polyelectrolytes, carrying alkyl side chains of different ...
Acevedo, Betsabé, Barraza, Raúl G., Olea, Andrés F., Salamanca, Constain H   +3 more
core   +1 more source

GBM radiosensitizers: dead in the water…or just the beginning? [PDF]

, 2017
The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control.
Bindra, Ranjit S., Chalmers, Anthony J., Dewhirst, Mark, Evans, Sydney   +3 more
core   +1 more source

Absence of a dose-rate effect in the transformation of C3H 10T1/2 cells by α-particles [PDF]

, 1987
The findings of Hill et al. (1984) on the greatly enhanced transformation frequencies at very low dose rates of fission neutrons induced us to perform an analogous study with -particles at comparable dose rates. Transformation frequencies were determined
Balcer-Kubiczek E.K., Barendsen G.W, Barendsen G.W., Borek C., Burch P.R.J., Elkind M.M., Hall E.J., Han A., Han A., Hill C.K., Hill C.K., Hill C.K., Lloyd E.L., Miller R.C., Miller R.C., Reznikoff C., Robertson J.B., Roos H., Rossi H.H., Terzaghi M., Yang T.   +20 more
core   +1 more source

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis [PDF]

, 2018
Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for ...
Alan H. Fairlamb, Alliance T.B., Altcheh J., Andrade H.M., Andrade S.G., Andrade S.G., Andrews K.T., Ang C.W., Araldi R.P., Aubé J., Bahia M.T., Bahia M.T., Balasubramanian B., Barreto-Bergter E., Berriman M., Bisser S., Blumenstiel K., Boiani M., Brener Z., Bruhn D.F., Bustamante J.M., Campos M.C., Campos M.C., Chung M.C., Collins A.R., Darsaud A., de Andrade A.L., Deavall D.G., Dikhit M.R., Docampo R., Docampo R., Docampo R., Dodd M.C., Dogra M., El-Sayed N.M., Enanga B., Eperon G., Fabbro D.L., Fairlamb A.H., Fairlamb A.H., Fairlamb A.H., Fernández M.L., Ferreira R.C., Filardi L.S., Fonseca-Berzal C., Garavaglia P.A., Goijman S.G., Gupta S., Gurumurthy M., Hall B.S., Hall B.S., Hayashi M., Henderson G.B., Henderson G.B., Henriques C., Ivens A.C., Jacobs R.T., Janssens P.G., Jeganathan S., Jennings F.W., Kaiser M., Kubata B.K., Lewis M.D., Lewis M.D., Lewis M.D., Likeufack A.C.L., Maina N., Makarov V., Marin-Neto J.A., Marin-Neto J.A., Matsumoto M., Maya J.D., Mejia A.M., Mejía-Jaramillo A.M., Mesu V.K.B.K., Miura K., Moens F., Molina I., Moreno M., Moreno S.N.J., Morillo C.A., Morillo C.A., Mortelmans K., Mukherjee T., Mukkavilli R., Murta S.M., Murta S.M.F., Murta S.M.F., Neal R.A., Nesslany F., Nogoceke E., Nogueira F.B., Nogueira F.B., Olmo F., Panicucci R., Papadopoulou M.V., Papadopoulou M.V., Papadopoulou M.V., Patterson S., Patterson S., Patterson S., Portal P., Priotto G., Priotto G., Pépin J., Pépin J., Raether W., Repetto Y., Rodriques Coura J., Romero A.H., Ryan N.J., Sasahara K., Shimokawa Y., Singh R., Smith D.A., Sokolova A.Y., Stephen Patterson, Stover C.K., Stuart K., Tarleton R.L., Tarral A., Temperton N.J., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Torreele E., Trochine A., Trochine A., Trunz B.B., Tweats D., Urbina J.A., Viodé C., Walsh J.S., Wilkinson S.R., Winkelmann E., Wyllie S., Wyllie S., Wyllie S., Wyllie S., Zhou L.   +141 more
core   +2 more sources

RRx-001, A novel dinitroazetidine radiosensitizer. [PDF]

, 2016
The 'holy grail' in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer-a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant ...
Bednarski, Mark, Cabrales, Pedro, Knox, Susan, Ning, Shoucheng, Oronsky, Arnold, Oronsky, Bryan, Peehl, Donna, Scicinski, Jan   +7 more
core   +1 more source

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection [PDF]

, 1998
In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection.
Bayerdörffer, Ekkehard, Bolle, Karl-Heinz, Höchter, Wilhelm, Klann, Hermann, Krämer, Walter, Lehn, Norbert, Meining, Alexander, Miehlke, Stephan, Simon, Thomas, Sommer, Albrecht, Stolte, Manfred, Weingart, Josef   +11 more
core   +1 more source

Microsomal superoxide anion production and NADPH-oxidation in a series of 22 aziridinylbenzoquinones [PDF]

, 1989
Several 2,5-bis(1-aziridinyl)-1,4-benzoquinones (BABQs) can be activated to alkylating species by reduction of the quinone moiety. On the other hand, cytotoxicity of these compounds can be induced by redox cycling.
Koster, Andries Sj., Prins, Bram, Reinhoudt, David N., Verboom, Willem   +3 more
core   +3 more sources

Exploring prospects of novel drugs for tuberculosis [PDF]

, 2012
Tuberculosis remains a disease with an enormous impact on public health worldwide. With the continuously increasing epidemic of drug-resistant tuberculosis, new drugs are desperately needed. However, even for the treatment of drug-sensitive tuberculosis,
Grobusch, M. P., Janssen, S., Jayachandran, R., Khathi, L., Pieters, J., Zinsstag, J.   +5 more
core   +1 more source

Toxicity prediction of anti tuberculosis active molecules [PDF]

, 2011
The aim of the work was to understand the toxicity, physically significant descriptors and pharmaceutically relevant properties of some imidazoles obtained from the open sources that may found to be active against tuberculosis.
Abdul Jaleel.U.C, Sajeev R
core   +2 more sources

The role of delamanid in the treatment of drug-resistant tuberculosis [PDF]

, 2015
Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed.
Lewis, Joseph M., Sloan, Derek James
core   +4 more sources